BCAB Stock Summary and Trading Ideas (Bioatla | NASDAQ:BCAB)

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Bioatla trades on the NASDAQ stock market under the symbol BCAB.

As of July 16, 2026, BCAB stock price declined to $3.99 with 23,365 million shares trading.

BCAB has a beta of 0.47, meaning it tends to be less sensitive to market movements. BCAB has a correlation of 0.00 to the broad based SPY ETF.

BCAB has a market cap of $6.61 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCAB traded as high as $201.00 and as low as $3.12.

The top ETF exchange traded funds that BCAB belongs to (by Net Assets): VXF.

BCAB has underperformed the market in the last year with a price return of -79.7% while the SPY ETF gained +21.9%. BCAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.4% and -2.3%, respectively, while the SPY returned +7.5% and +0.7%, respectively.

BCAB support price is $3.92 and resistance is $4.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAB shares will trade within this expected range on the day.